As key members of Memorial Sloan Kettering’s disease management teams, physicians in the Division of Solid Tumor Oncology collaborate with other medical specialists to customize each patient’s treatment based on his or her individual disease. Many of our members are nationally and internationally recognized as leaders in their fields, including those who serve as heads of professional organizations and as editors of leading specialty journals.
Our division is led by Luis Diaz, Jr., MD.
Breast Medicine Service
Our Breast Medicine Service is the leading breast cancer group in New York and one of the finest in the world. Our advances in research and treatment have resulted in the current standard of care for many breast cancer types and stages. We’ve also been leaders in the development of treatments such as trastuzumab (Herceptin®) and dose-dense chemotherapy programs, improving the options available for women across the United States and around the world.
Section Head, Endocrine Therapy Research Program; Clinical Director, Early Drug Development Service; Patricia and James Cayne Chair for Junior Faculty
Associate Attending Physician
Physician Site Director, Ralph Lauren Center
Consultant
Director of Clinical Operations, Evelyn H. Lauder Breast Center
Senior Vice President, Office of the President; Medical Director, Evelyn H. Lauder Breast Center; Norna S. Sarofim Chair in Clinical Oncology
Chief, Breast Medicine Service
Enid A. Haupt Chair in Medical Oncology
Attending Physician
Vice Chair of Outpatient Operations, Department of Medicine; Section Head, Triple Negative Breast Cancer Clinical Research Program
Assistant Attending Physician
Assistant Attending Physician
Associate Attending Physician
Assistant Attending Physician
Assistant Attending Physician
Assistant Attending Physician
Assistant Attending Physician
Assistant Attending Physician
Associate Attending Physician
Assistant Attending Physician
Director, Rare Breast Cancer Program, Department of Medicine; Co-Section Head, Triple Negative Breast Cancer Clinical Research Program, Department of Medicine
Assistant Attending Physician
Assistant Attending Physician
Assistant Attending Physician
Assistant Attending Physician
Co-Director, Breast Molecular Tumor Board
Assistant Attending Physician
Assistant Attending Physician
Director of Liquid Biopsy & Genomics
Regional Care Network Medical Site Director, MSK Monmouth
Associate Attending Physician
Assistant Attending Physician
Attending Physician
Attending Physician
Attending Physician
Naddisy Foundation Chair in Breast Cancer Research at Memorial Sloan Kettering
Attending Physician
Associate Attending Physician
Medical Site Director, MSK Bergen
Assistant Attending Physician
Attending Physician
Associate Attending Physician
Head & Neck Oncology Service
Our Head and Neck Oncology Service has changed the way cancers of the head and neck are treated. Our contributions to the field include helping to define the role of larynx preservation and, more recently, expanding the treatment options available to thyroid cancer patients. The group commonly manages rare cancers such as salivary gland tumors and anaplastic thyroid cancers.
Physician Consultant
Assistant Attending Physician
Regional Care Network (RCN) Medical Site Director at MSK Westchester
Assistant Attending Physician
Attending Physician
Attending Physician
Associate Deputy Physician-in-Chief, Strategic Partnerships
Assistant Attending Physician
Chief, Head and Neck Oncology Service; Associate Attending Physician
Attending Physician
Gastrointestinal Oncology Service
The Gastrointestinal Oncology Service has more than a dozen subspecialists, each focused on a single malignancy of the GI tract, including esophageal, gastric, pancreatic, liver, and colon cancer. Our faculty regularly treat rare diseases such as carcinoid neuroendocrine tumors and tumors of the gallbladder. New drug development programs, treatment approaches for cancers of unknown origin, and our intrahepatic chemotherapy program are all part of the team’s broad palette of expertise.
Associate Attending Physician
Winthrop Rockefeller Endowed Chair of Medical Oncology; Chair, Human Research Protection Program and Institutional Review Board; Co-Director, Medical Initiatives, David M. Rubenstein Center for Pancreatic Cancer Research; Section Head, Hepatopancreaticobi
Attending Physician
Assistant Attending Physician
Section Head, Colorectal Cancer; Co-Director, Center for Young Onset Colorectal and Gastrointestinal Cancers
Assistant Attending Physician
Assistant Attending Physician
Assistant Attending Physician
Associate Attending Physician
Head of the Division of Solid Tumor Oncology; Grayer Family Chair
Assistant Attending Physician
Associate Attending Physician
Assistant Attending Physician
Assistant Attending Physician
Associate Attending Physician
Associate Attending Physician
Associate Attending Physician
Attending Physician
Chief, Gastrointestinal Oncology Service
Assistant Attending Physician
Edward S. Gordon Chair in Medical Oncology
Assistant Attending Physician
Associate Attending Physician
Associate Attending Physician
Assistant Attending Physician
Assistant Attending Physician
Assistant Attending Physician
Vice Chair, Quality Assurance, Department of Medicine; Medical Site Director, Laurence S. Rockefeller Outpatient Pavilion at 53rd Street
Assistant Attending Physician
Vice Chair of Oncology Operations, Regional Care Network; Past President, MSK Medical Staff; Creator and Host, Cancer Straight Talk Podcast
Executive Director for Clinical Value & Sustainability; Head, Colorectal Oncology Section
Chair, Department of Medicine, George J. Bosl Chair at Memorial Sloan Kettering Cancer Center
Research Director, Division of Gastrointestinal Oncology
Associate Attending Physician
Instructor
Clinical Director, Clinical Genetics Service
Medical Site Director, MSK Nassau; Medical Director, Strategic Partnerships
Associate Attending Physician
Attending Physician
Assistant Attending Physician
Associate Attending Physician
Clinical Director, Gastrointestinal Oncology Service
Gynecologic Medical Oncology Service
The Gynecologic Medical Oncology Service is the largest in the United States. The group is a leader in vaccines, immunotherapy, and new drug development for gynecologic malignancies. We provide care for patients with uterine sarcomas and trophoblastic disease, as well as ovarian, tubal, endometrial, and cervical cancers.
Section Head, Ovarian Cancer; Director, Gynecologic Medical Oncology, MSK Westchester
Clinical Director, Gynecologic Medical Oncology Service; Attending Physician
Chief, Gynecologic Medical Oncology Service; Avon Chair in Gynecologic Oncology Research
Instructor
Assistant Attending Physician
Associate Attending Physician
Assistant Attending Physician
Assistant Attending Physician
Assistant Attending Physician
Assistant Attending Physician
Assistant Attending Physician
Attending Physician
Assistant Attending Physician
Lead, Inherited Gynecologic Cancer Program
Assistant Attending Physician
Assistant Attending Physician
Assistant Attending Physician
Assistant Attending Physician
Senior Vice President for Clinical Research
Research Director, Gynecologic Medical Oncology Service; Clinical Director, Solid Tumor, Cellular Therapy Service; Associate Attending Physician
Section Head, Endometrial Cancer Program; Director, Hematology-Medical Oncology Fellowship Training Program; Associate Attending Physician
Attending Physician, Gynecologic Medical Oncology, Associate Vice Chair, Academic Affairs; Chair, Promotions Advisory Committee
Genitourinary Oncology Service
The Genitourinary Oncology Service treats a wide spectrum of cancers — including those of the testes, kidney, bladder, and prostate — and has set national standards of care. Along with just a handful of others in the United States, our team helped to make testicular cancer into a highly curable malignancy and now leads the way in addressing survivorship issues. Our kidney cancer experts have led or co-led the development of every approved drug for that disease and continue to work on new and better treatments. Our bladder cancer team has pioneered new chemotherapy treatments and genetic studies. Our prostate cancer program includes nationally recognized experts in biomarker development and use and has led the way in the development and approval of both enzalutamide and abiraterone, changing the face of treatment for men with the disease.
Chief, Genitourinary Oncology Service, Division of Solid Tumor Oncology; Enno W. Ercklentz, Jr. Chair
Prostate Cancer Section Head, Genitourinary Oncology; Steven A. Greenberg Chair in Prostate Cancer Research
Director of Translational Research in Prostate Cancer; Associate Attending Physician, Genitourinary Oncology
Assistant Attending Physician
Assistant Attending Physician
Assistant Attending Physician
Frederick R. Adler Senior Faculty Chair
Assistant Attending Physician
Assistant Attending Physician
Attending Physician
Instructor
Assistant Attending Physician
Associate Attending Physician
Assistant Attending Physician
Section Head, Germ Cell Cancer
Assistant Attending Physician
Assistant Attending Physician
Section Head, Bladder Cancer
Consultant
Assistant Attending Physician
Assistant Attending Physician
Assistant Attending Physician
Assistant Attending Physician
Assistant Attending Physician
Assistant Attending Physician
Assistant Attending Physician
Section Head, Kidney Cancer, Genitourinary Oncology Service; Jack and Dorothy Byrne Chair in Clinical Oncology
Assistant Attending Physician
Attending Physician; Chair, Research Council
Attending Physician
Head, Biomarker Development Program; D. Wayne Calloway Chair in Urologic Oncology
Assistant Attending Physician
Associate Vice Chair, Academic Affairs, Department of Medicine
Geoffrey Beene Chair; Director, Marie-Josée and Henry R. Kravis Center for Molecular Oncology
Clinical Director, Genitourinary Medical Oncology Service
Assistant Attending Physician
Attending Physician
Assistant Attending Physician
Melanoma Service
The Melanoma Service is made up of five super-specialized medical oncologists with broad expertise in the treatment of melanoma in all its forms. The melanoma group has pioneered the development of immunotherapies such as ipilimumab and small-molecule targeted therapies such as vemurafenib. No other area in the field of oncology is moving faster than the treatment of melanoma, and our team has written and directed many of the recent trials leading to the approval of new treatments.
Medical Director, Strategic Partnerships; Clinical Director, Melanoma Service
Associate Attending Physician
Assistant Attending Physician
Assistant Attending Physician
Chief, Melanoma Service; Co-Director, Melanoma Disease Management Team
Sarcoma Medical Oncology Service
Our Sarcoma Medical Oncology Service is one of the most experienced and successful groups in the United States. Our group specializes in the care and management of this rare and diverse group of malignancies, enrolling many of our patients in targeted clinical trials. The team holds a large National Cancer Institute grant (the SPORE grant) to carry out sarcoma research.
Chief, Sarcoma Medical Oncology Service
Assistant Attending Physician
Assistant Attending Physician
Instructor
Co-Director, Sarcoma Translational Research, MSK Sarcoma Center
Associate Attending Physician
Associate Attending Physician
Physician Ambassador to India and Asia
Interim Clinical Director, Sarcoma Oncology Service
Associate Attending Physician
Attending Physician
Assistant Attending Physician
Division Head, Pediatric Solid Tumors; Chief, Pediatric Sarcoma Service
Assistant Attending Physician
Thoracic Oncology Service
The Thoracic Oncology Service is changing how thoracic cancer is treated. Drawing on the careful genetic analysis of lung cancers, we have subdivided this group of diseases into smaller subsets, each sensitive to highly specific anticancer treatments that can often be given in pill form. These treatments are spurring remarkable changes among patients with advanced lung cancers who would otherwise receive classic chemotherapy.
Cancer Center Deputy Director; Co-Director, Druckenmiller Center for Lung Cancer Research; Sylvia Hassenfeld Chair in Lung Cancer Research
Assistant Attending Physician
Chief, Thoracic Oncology Service
Attending Physician
Assistant Attending Physician
Instructor
Assistant Attending Physician
Assistant Attending Physician
Chief, Early Drug Development Service
Assistant Attending Physician
Assistant Attending Physician
Associate Attending Physician
Instructor
William and Joy Ruane Chair in Thoracic Oncology
Instructor
Enid A. Haupt Chair in Therapeutic Research
Attending Physician
Co-Director, Mesothelioma Program; Assistant Attending Physician
Clinical Director, Thoracic Oncology Service
Assistant Attending Physician
Ning Zhao and Ge Li Chair in Lung Cancer Research; Vice Chair of Clinical Research, Department of Medicine
Assistant Attending Physician
Assistant Attending Physician
Assistant Attending Physician
Associate Attending Physician
Clinical Genetics Service
The Clinical Genetics Service has made important contributions to the field, discovering both cancer susceptibility genes such as BRCA2 and characterizing how other genes alter the function of cancer genes. Through counseling of our patients and their families, this team provides a critical component of our cancer prevention programs in breast, ovarian, and colon cancers.
Chief, Clinical Genetics Service; Robert and Kate Niehaus Chair in Inherited Cancer Genomics; Vice Chair, Academic Affairs, Department of Medicine
Chief, Breast Medicine Service
Assistant Attending Physician
Associate Attending Physician
Medical Director, MSK-CATCH
Lead, Inherited Gynecologic Cancer Program
Clinical Director, Clinical Genetics Service
Early Drug Development Service
The Early Drug Development Service is made up of physicians, scientists, nurses, and research professionals. We collaborate closely with scientists from the Department of Medicine, the Human Oncology & Pathogenesis Program, and the Sloan Kettering Institute.
Our unique group works closely together to identify the next wave of potentially transformative cancer medicines. We treat patients with all different types of cancer and many of the new therapies we are testing are personalized based on the characteristics of each patient’s cancer.
Learn more about the Early Drug Development Service.
Chief, Early Drug Development Service
Assistant Attending Physician
Director of Targeted Radionuclide Therapy
Assistant Attending Physician
Associate Attending Physician
Director IR at Koch
Assistant Attending Physician
Physician Ambassador to India and Asia
Associate Attending Physician
Assistant Attending Physician
Associate Attending Physician
Assistant Attending Radiation Oncologist
Assistant Attending Radiation Oncologist
Section Head, Bladder Cancer
Section Head, Endocrine Therapy Research Program; Clinical Director, Early Drug Development Service; Patricia and James Cayne Chair for Junior Faculty
Chief, Neuro-Oncology and Cancer Neurology Service; Vice Chair for Clinical Research, Department of Neurology; Chair, Institutional Review Board (IRB-C)
Assistant Attending Physician
Laboratory Head, Human Oncology and Pathogenesis Program (HOPP); Member Investigator, Center for Cell Engineering
Attending Physician
Assistant Attending Physician
Vice Chair, Experimental Therapeutics, Department of Radiation Oncology; Service Chief, Head & Neck Radiation Oncology; Service Chief, Proton Therapy
Attending Physician
Assistant Attending Physician
Director, Nuclear Medicine Pediatrics
Associate Director, Genomics Operations, Immunogenomics and Precision Oncology Platform
Director of Colorectal and Anal Cancer, Department of Radiation Oncology
Assistant Attending Physician
Assistant Attending Physician
Assistant Attending Physician
Chief, Pediatric Translational Medicine Service (PTMS); Bristol-Myers Squibb/James D. Robinson III Junior Faculty Chair
Chief, Leukemia Service; Director, Program for Drug Development in Leukemia, Division of Hematologic Malignancies
Attending Physician
Associate Attending Physician
Lab Head